IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Dolores J. SCHENDEL

Serial No. 08/881,509

Filed: June 24, 1997

MAR 1 2 2001 E

RECEIVED

MAR 1 4 20011

Group Art Unit: 1644 TECH CENTER 1600/290

Examiner: A. DeCloux

For: T CELLS SPECIFIC FOR KIDNEY CARCINOMA

## **AMENDMENT UNDER 37 CFR § 1.116**

Commissioner for Patents Washington, D.C. 20231

March 12, 2001

Sir:

This paper is filed in response to the Office Action dated December 13, 2000, in connection with the above-identified patent application. Applicant respectfully requests entry of the following amendments.

## In the Claims:

-3.38.01 enfecol OKto Please amend claims 2 and 4 as follows. Attached is a marked up copy of the claims showing all changes to the claims.

Claim 2 (Amended). Isolated nucleic acid which codes for the α chain of a human T cell receptor, a single chain T cell receptor or a soluble T cell receptor fragment and comprises a CDR3 region selected from:

(a) a nucleotide sequence coding for the amino acid sequence (SEQ ID NO: 23)

 $YCL(X_1...X_n)SARQLTF$ 

in which  $X_1$  . . .  $X_n$  represents a sequence of 3-5 amino acids, wherein